Methods Data from the recent nationally representative household surveys, the National Health and Nutrition Examination Survey (NHANES) 2003-2010, learn more were used to estimate the number of HCV-infected persons in the United States. Data from the Chronic Hepatitis Cohort Study (CHeCS), an ongoing observational cohort study among patients receiving care at 4 integrated U.S. healthcare systems, were used to estimate the distribution (percent) by fibrosis stage among infected persons who had been diagnosed and biopsied. We further estimated the number of HCV-infected persons with liver fibrosis by using FIB4 cutoff of 1.5 (FIB4≥ 1.5 is predictive of Metavir stage F2 or higher) from CHeCS (among persons with

diagnosed HCV infection) and NHANES (HCV infection diagnosed or undiag-nosed). Results Among the 2.7 million civilian non-institutionalized persons with HCV infection R428 datasheet in the U.S., 1.35 million (50%) were assumed to have been diagnosed.

Estimating from CHeCS, among persons living with a diagnosed HCV infection (excluding those who had achieved virologic cure, died or liver transplanted), 32 %had a liver biopsy in 2004 or later, corresponding to 432,000 persons nationwide (32 %of 1.35 million). Of those biopsied, the most recent biopsy was staged at Metavir F2 or higher for 56 %of patients, corresponding to 242,000 patients nationwide, including 125,000 at F2 stage, 65,000 F3, and 52,000 F4. Among the 1.35 million HCV-in-fected persons who had been diagnosed, the percent with FIB4 score ≥ 1.5 was 57%. This percent corresponds to 770,000 diagnosed patients nationwide (57 %of 1.35 million). Of the 2.7 million HCV-infected persons in the United States,

995,000 (95 %confidence interval 837,000 to 1,250,000) persons had FIB4 score ≥ 1.5, with mean age of 54 years. Conclusions About 1 million non-institutionalized persons with HCV infection in the United States had a FIB4 score predictive of Metavir F2 or worse liver fibrosis. National estimates from this study may help policy makers develop guidelines for HCV therapy. Disclosures: The following people have nothing to disclose: Fujie Xu, Andrew J. Leidner, Xin Tong, Scott D. Holmberg Purpose: AASLD & IDSA recommend up to 48 wks of sofos-buvir (SOF) & ribavirin 上海皓元 (RBV) for pre-liver transplant (LT) HCV. HCV therapy can prevent post-LT graft infection and may avoid LT. However, sustained virologic response (SVR) rates are low in cirrhotics and patients may not survive to gain benefit. As SOF is expensive, deferring therapy until post-LT for 24 wks seems an attractive alternative. Mathematical modeling examined projected outcomes and cost-effectiveness of SOF/RBV in the pre- & post-LT periods. Methods: A Markov model was used to compare two strategies in HCV+ patients awaiting deceased donor LT: 1) SOF/RBV from listing to transplant (max: 48 wks) vs. 2) SOF/RBV for 24 wks deferred to post-LT.